PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 1, 2016Blood286 citationsOpen Access

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor

LLLauren Y. LeeDHDaniela HernandezTRTrivikram Rajkhowa

Key Points

Key points are not available for this paper at this time.

Abstract

To the editor: FLT3-activating mutations are one of the most frequent genetic aberrations in acute myeloid leukemia (AML).11 Internal tandem duplication (FLT3-ITD) mutations are associated with the worst prognosis, whereas tyrosine kinase domain (FLT3/TKD) mutations have an uncertain prognostic

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lee et al. (2016) studied this question.

synapsesocial.com/papers/6a63e3bd8553b4339ab36662https://doi.org/10.1182/blood-2016-10-745133
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Role of the KIT protooncogene in normal and malignant human hematopoiesis.1992 · 135 citations
  2. 2c-kit Ligand and Flt3 Ligand: Stem/Progenitor Cell Factors With Overlapping Yet Distinct Activities1998 · 702 citations
  3. 3Antitumor activity of sorafenib in FLT3-driven leukemic cells2007 · 169 citations
  4. 4PKC412--a protein kinase inhibitor with a broad therapeutic potential.2000 · 271 citations
  5. 5FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML2009 · 241 citations